MarketInOut Stock Screener Log In | Sign Up

4basebio Plc

LSE • Healthcare • Biotechnology • Quote as of 10/30/2026
4basebio Plc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeLSE
Market Capitalization81.45 mln
Float4.67 mln
Earnings Date06/02/2027

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-1.01
Manipulation likely

1-Year Forecast

1,225.00
Transformational upside

Relative Strength

59 / 100
Slightly ahead

Debt / Equity

18.18
Extremely leveraged

Pre-Tax Margin

-2,378%
Severely loss-making

Business Description

Founded in 2008 and headquartered in Cambridge, UK, 4basebio PLC develops and manufactures advanced DNA and RNA materials used in gene therapies, vaccines, and genome editing applications. The company produces a range of specialized synthetic DNA products designed for different scientific and medical purposes, along with a proprietary delivery platform called Hermes that transports genetic and protein materials without relying on traditional fat-based systems. 4basebio serves customers across Europe, the United States, and other international markets.

Key Fundamentals

EPS-116
ROE-178
RPS0.05
ROIC-158
ROA-57.81
Interest Cover-18.24
EBITDA, mln-16.48
EV / EBITDA-5.53
EV / EBIT-5.17
Revenue, mln0.78
EV / Revenue117

Quote Details

Last 526.00
Change -34 (-6.07%)
Open 526.00
Volume 200
Turnover 105,200
Average Volume 968.95

Financial Ratios

Pre-Tax Profit Margin-2,378
Leverage Ratio21.33
Current Ratio5.98
Price / Book64.63
Debt / Equity18.18
Price / Sales106

Financial Strength

Altman Z-Score-1.15
Piotroski F-Score 4 / 9
Beneish M-Score-1.01
1-Year Target Price1,225.00

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.19% 53 / 100   
1 Month -4.36% 30 / 100   
2 Months 3.14% 76 / 100   
6 Months 2.63% 53 / 100   
1 Year -30.83% 9 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog